Spanish clinical-stage biotechnology company founded in 2024 at San Sebastian in the Basque Country developing GGB-1, described as the first pharmaceutical intervention aimed at reducing and preventing falls and freezing of gait in people with Parkinson's disease, which received FDA investigational new drug approval in 2025.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen